Principal Financial Group
ARQT icon

Principal Financial Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Principal Financial Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.82M Buy
183,662
+14,836
+9% +$346K ﹤0.01% 1675
2026
Q1 		$3.98M Buy
+168,826
New +$4.31M ﹤0.01% 1687
2024
Q3 		– Sell
-18,555
Closed -$173K – 2238
2024
Q2 		$173K Sell
18,555
-570
-3% -$5.16K ﹤0.01% 2163
2024
Q1 		$190K Buy
19,125
+705
+4% +$5.26K ﹤0.01% 2186
2023
Q4 		$59.5K Buy
18,420
+3,336
+22% +$9.07K ﹤0.01% 2317
2023
Q3 		$80.1K Buy
15,084
+148
+1% +$1.26K ﹤0.01% 2312
2023
Q2 		$142K Buy
14,936
+1,553
+12% +$17.2K ﹤0.01% 2233
2023
Q1 		$147K Sell
13,383
-979
-7% -$14.2K ﹤0.01% 2233
2022
Q4 		$213K Buy
14,362
+2,654
+23% +$46.4K ﹤0.01% 2179
2022
Q3 		$223K Buy
11,708
+621
+6% +$14.1K ﹤0.01% 2176
2022
Q2 		$236K Buy
+11,087
New +$227K ﹤0.01% 2249
2021
Q4 		– Sell
-9,951
Closed -$238K – 2536
2021
Q3 		$238K Sell
9,951
-1,611
-14% -$36.7K ﹤0.01% 2382
2021
Q2 		$316K Buy
+11,562
New +$326K ﹤0.01% 2339

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Principal Financial Group's ARQT Position: Q2 2026 in Review

Principal Financial Group increased its Arcutis Biotherapeutics (ARQT) stake by 8.8% in Q2 2026, buying an estimated $346K and bringing the position to 183,662 shares worth $4.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1675.

Principal Financial Group first reported a position in ARQT in Q2 2021 and has held it in 13 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Principal Financial Group held 183,662 shares of Arcutis Biotherapeutics worth $4.82M as of Q2 2026.
  • Principal Financial Group bought 14,836 Arcutis Biotherapeutics shares in Q2 2026, an estimated $346K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #1675 holding.
  • Principal Financial Group first reported a position in Arcutis Biotherapeutics in Q2 2021 and has held it in 13 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.